| Literature DB >> 32381136 |
H M Veereschild1, E O Noorthoorn1, H L I Nijman2,3, C L Mulder4,5, M Dankers6, J A Van der Veen1, A J M Loonen7, G J M Hutschemaekers3,8.
Abstract
BACKGROUND: While polypharmacy is common in long-term residential psychiatric patients, prescription combinations may, from an evidence-based perspective, be irrational. Potentially, many psychiatric patients are treated on the basis of a poor diagnosis. We therefore evaluated the DITSMI model (i.e., Diagnose, Indicate, and Treat Severe Mental Illness), an intervention that involves diagnosis (or re-diagnosis) and appropriate treatment for severely mentally ill long-term residential psychiatric patients. Our main objective was to determine whether DITSMI affected changes over time regarding diagnoses, pharmacological treatment, psychosocial functioning, and bed utilization.Entities:
Keywords: Appropriate care; medication and hospital bed utilization; re-diagnose; severe mental illness
Mesh:
Year: 2020 PMID: 32381136 PMCID: PMC7358634 DOI: 10.1192/j.eurpsy.2020.46
Source DB: PubMed Journal: Eur Psychiatry ISSN: 0924-9338 Impact factor: 5.361
Patient characteristics before and after the implementation of the DITSMI model
|
| Before | After |
|
|---|---|---|---|
| Mean age | 49 (SD 11.8) | 52 (SD12.7) | |
| Mean duration of care history | 21 (SD 8.9) | 24 (SD 8.3) | |
| % men | 69% | 69% | |
| % partner | 18% | 18% | |
| Developmental disorder (autism, PDD-NOS ADHD) | 6% | 16% | 0.028 |
| Psychosis NOS | 8% | 19% | 0.043 |
| Schizophrenia | 53% | 36% | 0.019 |
| Schizoaffective disorder | 8% | 10% | 0.773 |
| Bipolar disorder | 8% | 2% | 0.031 |
| Depressive disorder | 5% | 4% | 0.731 |
| Personality disorder | 4% | 2% | 0.173 |
| PTSD | 1% | 5% | 0.093 |
| Mild or borderline intellectual functioning | 4% | 18% | 0.002 |
| Pedophilia | – | 1% | – |
| Substance-abuse | 21% | 16% | 0.419 |
| % of resident patients | 100% | 60% | <0.001 |
| Patients’ mean (SD) overall length of stay in years | 20.2 (8.7) | 22.6 (9.0) | <0.001 |
| Patients’ mean (SD) length of stay in years since 2000 | 13.6 (7.8) | 15.4 (7.2) | <0.001 |
| First-generation antipsychotic medication | 44% | 25% | 0.010 |
| Second-generation antipsychotic medication | 56% | 75% | 0.009 |
| Clozapine | 25% | 39% | 0.030 |
| Anticholinergic medication use | 35% | 19% | 0.023 |
| BMI (mean, SD) | 27.7 (5.0) | 30.4 (5.3) | 0.323 |
| Side effects | 38% | 23% | 0.028 |
| Diagnosis changed | 49% | ||
| Treatment proposal changed | 67% | ||
| Medication changed | 67% | ||
| Somatic comorbidity | 53% | ||
| Was provided psychotherapy | 16% | ||
| Relapse as defined by coercive measure or transfer to intensive care wards | 15% | ||
| Discharge | 35% | ||
| Deceased | 7% |
Abbreviations: PDD-NOS, Pervasive Developmental Disorder Not Otherwise Specified; ADHD, attention deficit hyperactivity disorder; Psychosis NOS, Psychosis Not Otherwise Specified BMI, body mass index; DITSMI, Diagnose, Indicate, Treat, Severe Mental Illness; PTSD, posttraumatic stress disorder; SD, standard deviation.
Figure 1.Changes in diagnoses of schizophrenia before and after the implementation of the model.
Main medication changes before and after the implementation of the DITSMI model
|
| Before | After |
|
|---|---|---|---|
| First-generation antipsychotic medication | 81 (22.1%) | 42 (12.9%) | <0.001 |
| Second-generation antipsychotic medication | 64 (21.2%) | 100 (30.7%) | <0.001 |
| Clozapine | 44 (12.0%) | 60 (18.2%) | 0.021 |
| Olanzapine | 14 (3.8%) | 36 (11.1%) | 0.003 |
| Biperideen | 46 (19.9%) | 24 (12.9%) | 0.026 |
| Benzodiazepines | 101 (27.2%) | 99 (29.8%) | 0.459 |
| Lorazepam | 36 (7.1%) | 52 (16%) | 0.018 |
| Oxazepam | 43 (11.7%) | 23 (7.1%) | 0.033 |
| Anticonvulsants | 33 (9.0%) | 29 (8.9%) | 0.931 |
| Antidepressant medication | 34 (9.2%) | 24 (7.3%) | 0.346 |
| SSRI | 24 (6.5%) | 19 (5.8%) | 0.673 |
| Tri-cyclic antidepressant | 10 (2.7%) | 5 (1.5%) | 0.273 |
| Number of prescriptions (denominator) | 370 | 332 |
Abbreviations: DITSMI, Diagnose, Indicate, Treat, Severe Mental Illness; SSRI, selective serotonin reuptake inhibitors.
Association between diagnosis, treatment proposal, and improvement on the HoNOS before and after implementation of the DITSMI model
|
| HoNOS below cut-off |
| |||
|---|---|---|---|---|---|
| Before | After | ||||
| Diagnosis | No change | 41 | 18 (44%) | 23 (56%) | 0.269 |
| Change in diagnosis | 41 | 16 (39%) | 25 (61%) | 0.041 | |
| Treatment proposal | No change | 29 | 13 (45%) | 16 (55%) | 0.430 |
| Change in treatment proposal | 53 | 21 (40%) | 32 (60%) | 0.032 | |
| 82 | 82 | ||||
A cut-off of 12 or less was used [16].
Figure 2.Length of stay of the cohort before, during, and after the treatment time frame.
Main changes in the following: the direct time (face-to-face contact) and indirect time (administration or consultation) spent by professionals; for this sample over 2015, 2016, and 2017
|
| 2015 | 2016 | 2017 |
|
|---|---|---|---|---|
| Indirect time in minutes | 10,773 | 12,108 | 8,651 | 0.001 |
| Direct time in minutes | 3,278 | 3,706 | 2,302 | 0.001 |
| Total time in minutes | 14,051 | 15,814 | 10,952 | 0.001 |